Who is sponsoring NCT03471481?

NCT03471481 is sponsored by Drexel University.

What drugs are being tested in NCT03471481?

Interventions in NCT03471481: No Intervention. Study is Cross Sectional in nature.

What condition does NCT03471481 study?

NCT03471481 studies Epilepsy, Magnesium Deficiency, Vitamin D Deficiency.

Is NCT03471481 still recruiting?

NCT03471481 is currently terminated. Last updated 1 March 2021.

Last reviewed 2021-03-01 · How we verify

NCT03471481

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy

Terminated Last updated 1 March 2021

What this trial tests

trial testing No Intervention. Study is Cross Sectional in nature in Epilepsy in 7 participants. Terminated before completion.

Timeline

10 August 2015

Primary endpoint
1 August 2019

1 August 2019

Quick facts

Lead sponsor	Drexel University
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	7
Start date	10 August 2015
Primary completion	1 August 2019
Estimated completion	1 August 2019
Sites	2 locations across United States

Drugs / interventions tested

No Intervention. Study is Cross Sectional in nature

Conditions studied

Epilepsy — all drugs for Epilepsy →
Magnesium Deficiency — all drugs for Magnesium Deficiency →
Vitamin D Deficiency — all drugs for Vitamin D Deficiency →

Sponsor

Drexel University

Who can join

Adults 18 to 70, any sex, with Epilepsy or Magnesium Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to determine the role of magnesium on bone and vitamin D metabolism in patients receiving anti-epileptic medications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other Drexel University trials

Trials by the same sponsor.

NCT07022808 — Tele-Exercise to Promote Empowered Movement in Individuals With Spinal Cord Injury · NA · not yet recruiting
NCT07165522 — Centering Autistic Perspectives in Behavioral Intervention Discussions · NA · not yet recruiting
NCT07225881 — Eatwell Clinical Trial (R01) · NA · recruiting
NCT06690372 — Improving Heart Health in Individuals With SCI Using Home-Based Virtual Gaming · NA · not yet recruiting
NCT06972381 — Piloting a Patient Navigator Program for Weight Loss · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03471481 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Drexel University
Last refreshed: 1 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03471481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing